A close look at current γδ T-cell immunotherapy

Ling Ma; Yanmin Feng; Zishan Zhou

doi:10.3389/fimmu.2023.1140623

A close look at current γδ T-cell immunotherapy

Front Immunol. 2023 Mar 31:14:1140623. doi: 10.3389/fimmu.2023.1140623. eCollection 2023.

Authors

Ling Ma^{1

2}, Yanmin Feng², Zishan Zhou²

Affiliations

¹ Institute of Molecular Medicine, College of Future Technology, Peking University, Beijing, China.
² Research and Development Department, Beijing Dingchengtaiyuan (DCTY) Biotech Co., Ltd., Beijing, China.

Abstract

Owing to their antitumor and major histocompatibility complex (MHC)-independent capacities, γδ T cells have gained popularity in adoptive T-cell immunotherapy in recent years. However, many unknowns still exist regarding γδ T cells, and few clinical data have been collected. Therefore, this review aims to describe all the main features of the applications of γδ T cells and provide a systematic view of current γδ T-cell immunotherapy. Specifically, this review will focus on how γδ T cells performed in treating cancers in clinics, on the γδ T-cell clinical trials that have been conducted to date, and the role of γδ T cells in the pharmaceutical industry.

Keywords: adoptive cell transfer (ACT); cancer immunotherapy; clinical trial; immunotherapy; γδ T cells.

Publication types

Review

MeSH terms

Humans
Immunotherapy
Immunotherapy, Adoptive
Intraepithelial Lymphocytes*
Neoplasms* / therapy
Receptors, Antigen, T-Cell, gamma-delta

Substances

Receptors, Antigen, T-Cell, gamma-delta